{"nct_id":"NCT04162210","title":"Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-05","start_date":"2020-04-02","start_date_type":"ACTUAL","primary_completion_date":"2022-09-12","primary_completion_date_type":"ACTUAL","completion_date":"2026-07-01","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["GSK"]}